active
ACTIVE SINCE: 2011

Bayer – Stop TB Partnership

Supporting countries in the treatment of multidrug-resistant tuberculosis (MDR-TB).
SGDS CONTRIBUTING TO:
MEMBER COMPANIES:
Global NGOs 1
Objectives
  • Support Stop TB Partnership in fighting MDR TB.

What are the health needs and challenges?

The current six-to eight-month standard therapy for tuberculosis (TB) is based on four drugs that were discovered more than 30 years ago and often have to be administered under the direct supervision of healthcare professionals. The long period makes consistent treatment more difficult to achieve, and the number of resistant strains of bacteria is therefore increasing. The available medicines are not effective against the multi-drug-resistant TB (MDR-TB) caused by resistant bacteria.

Partnership activities and how they address needs and challenges

In 2011 Bayer agreed with the World Health Organization (WHO) to support countries in the treatment of multidrug-resistant tuberculosis (MDR-TB) with moxifloxacin, a well-known antibiotic for the treatment of acute respiratory infection as well as other infections with an established safety record.

The collaboration with the WHO includes the involvement in a program designed to support increased access to quality-assured second-line anti-tuberculosis which targets to increase treatment success against MDR-TB and thereby could also reduce the likelihood for further resistance development to anti tuberculosis drug.

STOP TB partnership of the WHO makes moxifloxacin available to MDR TB patients in need under specifically defined conditions of treatment programs authorized by the STOP-TB Partnership in collaboration with national TB treatment programs.

Results and milestones

Sixteen countries have joined the program since December 2011. A total of around 1.3 million moxifloxacin tablets were supplied to six countries (China, Georgia, Armenia, Haiti, Russia and Indonesia) in 2013. This quantity of the drug enables the treatment of a good 2,450 MDR-TB patients for the minimum treatment period of 18 months.

Geographic Reach
  • Africa
  • Americas
  • Europe
  • South-East Asia
  • Western Pacific
See Where
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Target Population
  • Men
  • Women
SGDs the partnership contributes to
SDG 3: Good health and well-being
  1. 3.3: Communicable diseases and NTDs
  2. 3.8: Achieve universal health coverage
SDG 5: Gender equality
SDG 17: Partnerships for the goals 
Partner organizations
Global NGOs

Stop TB Partnership